Log in

NASDAQ:ALECAlector Stock Price, Forecast & News

$15.48
-0.19 (-1.21 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.31
Now: $15.48
$16.06
50-Day Range
$15.67
MA: $24.18
$31.12
52-Week Range
$13.64
Now: $15.48
$35.93
Volume1.51 million shs
Average Volume678,728 shs
Market Capitalization$1.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.63
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALEC
CUSIPN/A
CIKN/A
Phone415-231-5660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.22 million
Book Value$2.83 per share

Profitability

Net Income$-105,390,000.00
Net Margins-556.70%

Miscellaneous

Employees91
Market Cap$1.22 billion
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable
$15.48
-0.19 (-1.21 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alector (NASDAQ:ALEC) Frequently Asked Questions

How has Alector's stock been impacted by COVID-19 (Coronavirus)?

Alector's stock was trading at $24.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALEC shares have decreased by 37.9% and is now trading at $15.48.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Alector?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alector
.

When is Alector's next earnings date?

Alector is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Alector
.

How were Alector's earnings last quarter?

Alector Inc (NASDAQ:ALEC) posted its earnings results on Wednesday, May, 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.10. The company had revenue of $7.17 million for the quarter, compared to the consensus estimate of $10.60 million. Alector had a negative net margin of 556.70% and a negative return on equity of 48.29%.
View Alector's earnings history
.

What price target have analysts set for ALEC?

8 equities research analysts have issued 12-month target prices for Alector's stock. Their forecasts range from $28.00 to $41.00. On average, they expect Alector's share price to reach $32.80 in the next twelve months. This suggests a possible upside of 111.9% from the stock's current price.
View analysts' price targets for Alector
.

Has Alector been receiving favorable news coverage?

News articles about ALEC stock have been trending extremely negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alector earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Alector
.

Are investors shorting Alector?

Alector saw a increase in short interest in June. As of June 30th, there was short interest totaling 5,760,000 shares, an increase of 11.6% from the June 15th total of 5,160,000 shares. Based on an average trading volume of 492,100 shares, the short-interest ratio is presently 11.7 days. Currently, 11.1% of the company's shares are sold short.
View Alector's Current Options Chain
.

Who are some of Alector's key competitors?

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Cisco Systems (CSCO), Harpoon Therapeutics (HARP), Johnson & Johnson (JNJ), Kaleido Biosciences (KLDO) and AT&T (T).

Who are Alector's key executives?

Alector's management team includes the following people:
  • Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
  • Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)
  • Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)
  • Dr. Robert S. King, Chief Devel. Officer (Age 56)
  • Dr. Asa Abeliovich M.D., Ph.D., Co-Founder

When did Alector IPO?

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Who are Alector's major shareholders?

Alector's stock is owned by a number of institutional and retail investors. Top institutional investors include First Trust Advisors LP (0.18%), ProShare Advisors LLC (0.02%), SG Americas Securities LLC (0.02%) and Strs Ohio (0.01%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire.
View institutional ownership trends for Alector
.

Which major investors are buying Alector stock?

ALEC stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Strs Ohio, ProShare Advisors LLC, and SG Americas Securities LLC. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc.
View insider buying and selling activity for Alector
.

How do I buy shares of Alector?

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $15.48.

How big of a company is Alector?

Alector has a market capitalization of $1.22 billion and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe.

What is Alector's official website?

The official website for Alector is www.alector.com.

How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.